Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$85.26
pos +0.12
+0.14%
Today's Range: 83.86 - 86.65 | GILD Avg Daily Volume: 10,568,500
Last Update: 02/08/16 - 4:14 PM EST
Volume: 19,003,465
YTD Performance: -15.85%
Open: $84.19
Previous Close: $85.14
52 Week Range: $81.89 - $123.37
Oustanding Shares: 1,441,180,186
Market Cap: 124,921,498,522
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 9
Moderate Buy 2 2 2 2
Hold 5 4 4 3
Moderate Sell 0 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.75 1.81 1.81 1.73
Latest Dividend: 0.43
Latest Dividend Yield: 1.98%
Dividend Ex-Date: 03/14/16
Price Earnings Ratio: 6.87
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
6.87 7.30 30.32
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-21.03% -14.77% 110.04%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 0.00 3.32 0.62
EPS 0.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 0.00B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $2.82 $2.89 $11.49 $11.60
Number of Analysts 2 2 2 2
High Estimate $2.95 $2.98 $11.93 $12.25
Low Estimate $2.68 $2.81 $11.04 $10.95
Prior Year $2.89 $3.10 $12.45 $11.49
Growth Rate (Year over Year) -2.60% -6.61% -7.75% 1.00%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
I am using the downturn to continue to build up positions in value stocks.
They offer impressive free cash flow, great balance sheets, evolving pipelines and nice dividend yields.
We have a flawed asset class that doesn't trade on anything but whim.
In a year's time, investors may look back and think this was a great entry point.
Results from a tech, biotech and restaurant stock will be particularly important.
Tech leads the way up while biotech lags behind.
Prices could find some support or buying interest at $80.
Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.

Columnist Conversations

I'm not at a major downside target yet in SPX, but I do have timing for a tradable bounce in the next few trad...
What the market bloodbath reinforces: always hold a realistic view of the future (dare I say, conservative).
Kelly Services had been strong this morning in the face of intense broad-based selling overall. The stock buil...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.